News
Impact Success Stories: Interview with Prof Caitriona O’Driscoll on GENEGUT
GENEGUT, an EU‑funded project coordinated by Prof Caitriona O’Driscoll, aims to develop a first in class oral RNA-based medicine for Crohn’s disease. In a recent interview with Health‑NCP‑Net 3.0, part of the Horizon Europe support network, she outlined GENEGUT’s goal and impact.
GENEGUT aims to deliver RNA directly to the site of inflammation in the gut using biodegradable nanoparticles. The approach offers a more targeted and less invasive alternative to existing treatments.
Speaking about the wider impact of the research, she said:
The interdisciplinary approach of the GENEGUT project will help to reduce the disease burden for CD patients, increase the quality of life, decrease hospitalisation, decrease work related sick leave, decrease the financial burden for healthcare providers, and improve the quality of healthcare.